Johnson & Johnson will pay New York $230 million to resolve an opioid lawsuit, the state’s attorney general announced Saturday.
As per a statement from New York AG Letitia James, Johnson & Johnson “has committed to cease manufacturing and selling opioids and opioid products in the state of New York, as well as no longer shipping these products anywhere in the United States.”
Johnson & Johnson settled its opioids lawsuit with the State of New York for $230 million
A company statement said the company “decided in 2020 to discontinue all prescription pain medications in the United States.”
Johnson & Johnson will not be subject to a trial that begins in New York on Tuesday. However, it remains subject to other lawsuits being brought by local governments, states, and Native American tribes across the US regarding opioids flow into their communities. According to court documents in Oklahoma, Johnson & Johnson paid $465 million to settle an opioid case in 2019.
James said that Johnson & Johnson contributed to the fire, but today the company is committing to leaving the opioid business – not just in New York, but across the country as well. J&J will no longer manufacture or sell opioids in the United States.
In a statement, GW Pharmaceuticals said it did not admit fault or wrongdoing in announcing the settlement, which conformed to the terms of the previously announced $5 billion all-in settlement agreement in principle to resolve opioid lawsuits by towns, states and counties.